AbbVie Unveils New Phase 3 Data on Venetoclax for CLL at EHA 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: PRnewswire
- Clinical Trial Results: AbbVie's presentation at the EHA 2026 Congress revealed that the CLL14 trial's nine-year data demonstrated significant safety and efficacy for the venetoclax and obinutuzumab combination, with a median progression-free survival (PFS) of 6.4 years compared to 3.2 years in the control group, indicating long-term effectiveness in chronic lymphocytic leukemia (CLL) patients.
- Extended Treatment Intervals: The study also highlighted a median time to next treatment (TTNT) of 7.6 years for patients receiving venetoclax plus obinutuzumab, allowing for longer periods without treatment, which not only enhances patient quality of life but also strengthens AbbVie's leadership position in blood cancer therapies.
- Safety Analysis: Among patients treated with the venetoclax combination, the most frequently reported Grade 3 adverse events included neutropenia and thrombocytopenia; however, the overall safety profile remains acceptable, laying a solid foundation for the clinical application of this therapy.
- Market Outlook: With venetoclax approved in over 80 countries, AbbVie's research findings not only bolster its competitive edge in the global market but also provide renewed impetus for further research and development in CLL and other hematological malignancies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 224.950
Low
223.00
Averages
252.00
High
289.00
Current: 224.950
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified, research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. The aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Duodopa is a levodopa-carbidopa intestinal gel for the treatment of Parkinson's disease. Eye care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AbbVie’s TrenibotE Program Receives FDA Complete Response Letter
- FDA Response Overview: AbbVie received a Complete Response Letter from the FDA in April 2026 regarding its biologics license application for TrenibotE, highlighting manufacturing-related concerns and requesting additional information, with no safety or efficacy issues raised.
- Product Characteristics Analysis: TrenibotE, a novel botulinum neurotoxin serotype E neuromodulator, is characterized by a rapid onset of effects, reported as early as eight hours post-administration, and a short duration of approximately two to three weeks, potentially appealing to patients wary of long-term commitments.
- Market Potential Exploration: Given that most aesthetic neuromodulators currently in use are based on botulinum toxin type A, TrenibotE's rapid onset may introduce a new direction in the field, catering to consumer demand for shorter-acting products.
- Company Outlook: AbbVie focuses on developing and marketing therapies across immunology, oncology, and neuroscience, and despite facing FDA challenges, the company is confident in its ability to promptly address the FDA's comments and continue advancing TrenibotE towards market approval.
See More
AbbVie Unveils New Phase 3 Data on Venetoclax for CLL at EHA 2026
- Clinical Trial Results: AbbVie's presentation at the EHA 2026 Congress revealed that the CLL14 trial's nine-year data demonstrated significant safety and efficacy for the venetoclax and obinutuzumab combination, with a median progression-free survival (PFS) of 6.4 years compared to 3.2 years in the control group, indicating long-term effectiveness in chronic lymphocytic leukemia (CLL) patients.
- Extended Treatment Intervals: The study also highlighted a median time to next treatment (TTNT) of 7.6 years for patients receiving venetoclax plus obinutuzumab, allowing for longer periods without treatment, which not only enhances patient quality of life but also strengthens AbbVie's leadership position in blood cancer therapies.
- Safety Analysis: Among patients treated with the venetoclax combination, the most frequently reported Grade 3 adverse events included neutropenia and thrombocytopenia; however, the overall safety profile remains acceptable, laying a solid foundation for the clinical application of this therapy.
- Market Outlook: With venetoclax approved in over 80 countries, AbbVie's research findings not only bolster its competitive edge in the global market but also provide renewed impetus for further research and development in CLL and other hematological malignancies.
See More
AbbVie Reveals Phase 3 CLL14 Trial Data at EHA 2026
- Clinical Trial Results: AbbVie's presentation at the EHA 2026 revealed that the Phase 3 CLL14 trial demonstrated a median progression-free survival (PFS) of 6.4 years for venetoclax combined with obinutuzumab, significantly outperforming the 3.2 years seen with obinutuzumab plus chlorambucil, underscoring the efficacy of this combination in treating previously untreated chronic lymphocytic leukemia (CLL) patients.
- Treatment Durability: The nine-year analysis indicated a median time to next treatment of 7.6 years for the venetoclax and obinutuzumab combination, providing patients with substantial time off treatment after a fixed-duration therapy, reflecting the long-term efficacy and safety of this treatment option.
- Patient Benefits: The findings highlight the positive responses of venetoclax in combination with obinutuzumab in previously untreated patients, particularly those with coexisting medical conditions, offering a limited-duration treatment option aimed at improving patient quality of life and treatment experience.
- Future Outlook: AbbVie is committed to advancing treatment options for blood cancers through such research, further solidifying its leadership in oncology and providing better therapeutic choices for patients, aligning with its mission to transform care and enhance patient outcomes.
See More
AbbVie Presents Phase 3 CLL14 Trial Data at EHA 2026
- Efficacy and Safety Confirmation: AbbVie's presentation at EHA 2026 revealed that the Phase 3 CLL14 trial demonstrated a median progression-free survival (PFS) of 6.4 years for venetoclax combined with obinutuzumab, significantly outperforming the 3.2 years seen with obinutuzumab plus chlorambucil, affirming the long-term efficacy and safety of this combination in chronic lymphocytic leukemia (CLL) patients.
- Extended Treatment Intervals: The study indicated a median time to next treatment of 7.6 years for patients receiving venetoclax plus obinutuzumab, providing significant off-treatment time after a fixed 12-month regimen, reflecting the tolerability and effectiveness of this treatment option.
- Strengthened Clinical Collaboration: Conducted in close collaboration with the German CLL Study Group, the trial enrolled 432 previously untreated CLL patients, underscoring AbbVie's commitment to research in hematologic cancers and laying the groundwork for future treatment strategies.
- Adverse Event Monitoring: Common grade 3 adverse events in patients receiving venetoclax combination therapy included neutropenia, thrombocytopenia, and infusion-related reactions, prompting AbbVie to continue monitoring these adverse effects to ensure patient safety.
See More
AbbVie Presents Nine-Year Results from CLL14 Trial at EHA 2026 Congress
- Clinical Trial Results: AbbVie's presentation at the EHA 2026 Congress revealed that the CLL14 trial demonstrated a median progression-free survival of 6.4 years for venetoclax plus obinutuzumab, significantly outperforming the control group's 3.2 years, indicating the long-term efficacy of this combination in chronic lymphocytic leukemia (CLL) patients.
- Treatment Durability: The study also found a median time to next treatment of 7.6 years for the venetoclax-obinutuzumab combination, showcasing a substantial duration of treatment-free time for patients, thereby enhancing their quality of life.
- Safety Profile: Among patients receiving the venetoclax combination therapy, common Grade 3 adverse events included neutropenia, thrombocytopenia, and infusion-related reactions; however, the overall safety profile remains acceptable, supporting its potential for clinical application.
- Market Implications: With venetoclax approved in over 80 countries, AbbVie's research findings not only solidify its leadership in the blood cancer treatment space but also lay the groundwork for future market expansion and the development of new therapeutic options.
See More
Analysis of VOOG ETF's 52-Week Price Fluctuations
- Price Range Analysis: VOOG ETF's 52-week low is $62.7167 per share and high is $85.3465, with the latest trade at $80.95, indicating relative stability in a volatile market, potentially attracting investors seeking steady returns.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides valuable insights for investors, helping them assess market trends and make more informed investment decisions.
- ETF Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting the liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs with significant inflows or outflows, where inflows necessitate purchasing underlying assets, while outflows may lead to selling, affecting the ETF's components.
See More
AbbVie’s TrenibotE Program Receives FDA Complete Response Letter
- FDA Response Overview: AbbVie received a Complete Response Letter from the FDA in April 2026 regarding its biologics license application for TrenibotE, highlighting manufacturing-related concerns and requesting additional information, with no safety or efficacy issues raised.
- Product Characteristics Analysis: TrenibotE, a novel botulinum neurotoxin serotype E neuromodulator, is characterized by a rapid onset of effects, reported as early as eight hours post-administration, and a short duration of approximately two to three weeks, potentially appealing to patients wary of long-term commitments.
- Market Potential Exploration: Given that most aesthetic neuromodulators currently in use are based on botulinum toxin type A, TrenibotE's rapid onset may introduce a new direction in the field, catering to consumer demand for shorter-acting products.
- Company Outlook: AbbVie focuses on developing and marketing therapies across immunology, oncology, and neuroscience, and despite facing FDA challenges, the company is confident in its ability to promptly address the FDA's comments and continue advancing TrenibotE towards market approval.
See More
AbbVie Unveils New Phase 3 Data on Venetoclax for CLL at EHA 2026
- Clinical Trial Results: AbbVie's presentation at the EHA 2026 Congress revealed that the CLL14 trial's nine-year data demonstrated significant safety and efficacy for the venetoclax and obinutuzumab combination, with a median progression-free survival (PFS) of 6.4 years compared to 3.2 years in the control group, indicating long-term effectiveness in chronic lymphocytic leukemia (CLL) patients.
- Extended Treatment Intervals: The study also highlighted a median time to next treatment (TTNT) of 7.6 years for patients receiving venetoclax plus obinutuzumab, allowing for longer periods without treatment, which not only enhances patient quality of life but also strengthens AbbVie's leadership position in blood cancer therapies.
- Safety Analysis: Among patients treated with the venetoclax combination, the most frequently reported Grade 3 adverse events included neutropenia and thrombocytopenia; however, the overall safety profile remains acceptable, laying a solid foundation for the clinical application of this therapy.
- Market Outlook: With venetoclax approved in over 80 countries, AbbVie's research findings not only bolster its competitive edge in the global market but also provide renewed impetus for further research and development in CLL and other hematological malignancies.
See More
AbbVie Reveals Phase 3 CLL14 Trial Data at EHA 2026
- Clinical Trial Results: AbbVie's presentation at the EHA 2026 revealed that the Phase 3 CLL14 trial demonstrated a median progression-free survival (PFS) of 6.4 years for venetoclax combined with obinutuzumab, significantly outperforming the 3.2 years seen with obinutuzumab plus chlorambucil, underscoring the efficacy of this combination in treating previously untreated chronic lymphocytic leukemia (CLL) patients.
- Treatment Durability: The nine-year analysis indicated a median time to next treatment of 7.6 years for the venetoclax and obinutuzumab combination, providing patients with substantial time off treatment after a fixed-duration therapy, reflecting the long-term efficacy and safety of this treatment option.
- Patient Benefits: The findings highlight the positive responses of venetoclax in combination with obinutuzumab in previously untreated patients, particularly those with coexisting medical conditions, offering a limited-duration treatment option aimed at improving patient quality of life and treatment experience.
- Future Outlook: AbbVie is committed to advancing treatment options for blood cancers through such research, further solidifying its leadership in oncology and providing better therapeutic choices for patients, aligning with its mission to transform care and enhance patient outcomes.
See More
AbbVie Presents Phase 3 CLL14 Trial Data at EHA 2026
- Efficacy and Safety Confirmation: AbbVie's presentation at EHA 2026 revealed that the Phase 3 CLL14 trial demonstrated a median progression-free survival (PFS) of 6.4 years for venetoclax combined with obinutuzumab, significantly outperforming the 3.2 years seen with obinutuzumab plus chlorambucil, affirming the long-term efficacy and safety of this combination in chronic lymphocytic leukemia (CLL) patients.
- Extended Treatment Intervals: The study indicated a median time to next treatment of 7.6 years for patients receiving venetoclax plus obinutuzumab, providing significant off-treatment time after a fixed 12-month regimen, reflecting the tolerability and effectiveness of this treatment option.
- Strengthened Clinical Collaboration: Conducted in close collaboration with the German CLL Study Group, the trial enrolled 432 previously untreated CLL patients, underscoring AbbVie's commitment to research in hematologic cancers and laying the groundwork for future treatment strategies.
- Adverse Event Monitoring: Common grade 3 adverse events in patients receiving venetoclax combination therapy included neutropenia, thrombocytopenia, and infusion-related reactions, prompting AbbVie to continue monitoring these adverse effects to ensure patient safety.
See More
AbbVie Presents Nine-Year Results from CLL14 Trial at EHA 2026 Congress
- Clinical Trial Results: AbbVie's presentation at the EHA 2026 Congress revealed that the CLL14 trial demonstrated a median progression-free survival of 6.4 years for venetoclax plus obinutuzumab, significantly outperforming the control group's 3.2 years, indicating the long-term efficacy of this combination in chronic lymphocytic leukemia (CLL) patients.
- Treatment Durability: The study also found a median time to next treatment of 7.6 years for the venetoclax-obinutuzumab combination, showcasing a substantial duration of treatment-free time for patients, thereby enhancing their quality of life.
- Safety Profile: Among patients receiving the venetoclax combination therapy, common Grade 3 adverse events included neutropenia, thrombocytopenia, and infusion-related reactions; however, the overall safety profile remains acceptable, supporting its potential for clinical application.
- Market Implications: With venetoclax approved in over 80 countries, AbbVie's research findings not only solidify its leadership in the blood cancer treatment space but also lay the groundwork for future market expansion and the development of new therapeutic options.
See More
Analysis of VOOG ETF's 52-Week Price Fluctuations
- Price Range Analysis: VOOG ETF's 52-week low is $62.7167 per share and high is $85.3465, with the latest trade at $80.95, indicating relative stability in a volatile market, potentially attracting investors seeking steady returns.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides valuable insights for investors, helping them assess market trends and make more informed investment decisions.
- ETF Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting the liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs with significant inflows or outflows, where inflows necessitate purchasing underlying assets, while outflows may lead to selling, affecting the ETF's components.
See More
